AC Immune SA - Company Profile
Powered by
All the data and insights you need on AC Immune SA in one report.
- Save hours of research time and resources with
our up-to-date AC Immune SA Strategy Report
- Understand AC Immune SA position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
AC Immune is a Switzerland-based biopharmaceutical company, which focuses on neurodegenerative diseases with four product candidates in clinical trials. The company's lead product candidate, Crenezumab, focus on research and development and technology platforms give it an edge over its peers in the industry, whereas history of operating losses remains a cause for concern. The fast track drug designation, pipeline products and the market potential for Alzheimer's disease could provide growth opportunities to the company. However, competitive pressures, government regulations and rapid technological changes could affect its operations.
Strengths
Weaknesses
Opportunities
Threats
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer